HUMORAL AND CELLULAR-RESPONSES OF COLORECTAL-CANCER PATIENTS TREATED WITH MONOCLONAL-ANTIBODIES AND INTERFERON-GAMMA

被引:13
作者
BLOTTIERE, HM
DOUILLARD, JY
KOPROWSKI, H
STEPLEWSKI, Z
机构
[1] WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104
[2] FAC MED NANTES,INSERM,U211,F-44034 NANTES,FRANCE
[3] CTR RENE GAUDUCHEAU,F-44034 NANTES,FRANCE
关键词
D O I
10.1007/BF01741721
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fifteen patients with metastatic gastrointestinal adenocarcinomas were treated with low doses of recombinant human interferon γ (rh-IFNγ) and a mixture of monoclonal antibodies (mAb) that bind to tumor cells. All antibodies were of the IgG2a isotype and interact with human effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Natural killer lysis against K562 cells by peripheral blood mononuclear cells purified from patients' blood was enhanced in all patients at day 3 during IFNγ treatment. Monocytes from two patients had increased ADCC levels. Increase in the percentage of monocytes able to bind mouse IgG2a was detected by Fc receptor flow cytometry analysis 24 h after the first IFNγ infusion. However, 3 days later, the percentage of fluorescent cells had fallen below baseline levels. The analysis of patients' sera showed that at day 2 after mAb infusion, only 50% of the circulating mouse IgG was immunoreactive, and after 1 week, only traces of immunoreactive mouse IgG were detected. All patients developed a human anti-(mouse Ig) response of IgG, IgM and IgA isotypes, although only low levels of anti-idiotypic antibodies were detected at the time of testing (up to 9 weeks) after mAb infusion. No difference in the IgG subclasses of anti-(mouse Ig) antibody was observed between patients treated with mAb and IFNγ and patients treated with mAb alone. © 1990 Springer-Verlag.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 42 条
  • [1] AKIYAMA Y, 1984, CANCER RES, V44, P5127
  • [2] BLASZCZYKTHURIN M, 1987, J BIOL CHEM, V262, P372
  • [3] BLOTTIERE HM, 1987, CANCER RES, V47, P5238
  • [4] BLOTTIERE HM, 1989, IN PRESS MONOCLONAL
  • [5] BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
  • [6] CHATAL JF, 1986, HYBRIDOMA, V5, pS87
  • [7] DEFRIES RU, 1988, J IMMUNOL, V140, P3686
  • [8] DOUILLARD JY, 1986, HYBRIDOMA, V5, pS139
  • [9] IMMUNOTHERAPY OF GASTROINTESTINAL CANCER WITH MONOCLONAL-ANTIBODIES
    DOUILLARD, JY
    LEMEVEL, B
    CURTET, C
    VIGNOUD, J
    CHATAL, JF
    KOPROWSKI, H
    [J]. MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY, 1986, 3 (3-4): : 141 - 146
  • [10] FINKELMAN FD, 1988, J IMMUNOL, V140, P1022